Status:
UNKNOWN
Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization
Lead Sponsor:
Asan Medical Center
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Twenty four patients with multiple myeloma will be randomized to either AM group (administration of lenograstim at 8 am) or PM group (administration of lenograstim at 6 am ). Apheresis of hematopoieti...
Eligibility Criteria
Inclusion
- age: above 17 years, below 65 years old
- informed consent
- ECOG 0-1
- autologous stem cell transplant candidate among patients with multiple myeloma
Exclusion
- prior history of hematopoetic stem cell transplantation
- history of failure to mobilize hematopoietic stem cells
- history of G-CSF administration within 2 weeks before enrollment to this study
Key Trial Info
Start Date :
July 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT02184897
Start Date
July 1 2014
End Date
December 1 2016
Last Update
July 26 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center, University of Ulsan College of Medicine
Seoul, South Korea, 138-736
2
Asan Medical Center
Seoul, South Korea, 1387-736